Mantle Cell Lymphoma
From the Journals
Survival ‘excellent’ after rituximab-bendamustine induction in transplant-eligible MCL
Investigators reported that the regimen’s efficacy is on par with R-hyperCVAD, but is less toxic.
Feature
ASCO to award $50,000 young investigator grant to study MCL
The award is a 1-year grant of $50,000 to pursue clinical research on mantle cell lymphoma.
From the Journals
Follow-up shows favorable results with acalabrutinib in MCL
The median duration of response exceeded 2 years with acalabrutinib monotherapy.
From the Journals
Staging PET/CT better defines extent of mantle cell lymphoma
This type of imaging altered stage and management in nearly one-fifth of cases.
From the Journals
Rituximab, bendamustine look better than chemo alone in MCL
The research confirms the benefit of adding novel agents to chemotherapy regimens in older patients with mantle cell lymphoma.
Conference Coverage
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCL
LUGANO, SWITZERLAND – In patients younger than 65 years old, two cycles of ibrutinib and rituximab followed by four cycles of chemotherapy...
Conference Coverage
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCL
LUGANO, SWITZERLAND –The chemotherapy-free combination was associated with a high objective response rate in patients with a median age of 71...
From the Journals
Low-dose radiation therapy looks effective in hard-to-treat MCL
The treatment approach can be used safely with concurrent chemotherapy.
From the Journals
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
The researchers said the findings cast doubt on the ability of this CDK inhibitor to be effective in B-cell lymphomas.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
Obinutuzumab provides strong early responses in untreated MCL
AMSTERDAM – A minimal residual disease rate as high as 85% is “unprecedented” in this population of patients, the lead investigator of the LYMA-...